We’re putting the finishing touches on something special — ordering opens soon. Stay tuned.
← Back to Catalog

Retatrutide

Retatrutide vial frontRetatrutide vial back
Loading...

Summary

LY3437943, RETA

Retatrutide is an investigational once-weekly injectable that activates three different hormone receptors involved in metabolism and appetite. In a Phase 2 trial, the highest dose produced an average weight loss of 24%, one of the largest reductions seen with any weight loss medication. It's currently in Phase 3 trials and not yet approved.

Current Research
  • Triple-receptor metabolic signaling (GLP-1 / GIP / glucagon)
  • Body weight in obesity research
  • Type-2 diabetes models
Identification
CAS
2381089-83-2
Formula
C223H343F3N46O70
M.W.
4731.33 g/mol

Key Research Statistics

Triple Hormone Receptor Agonist

28.7%Max Weight LossPhase 3, 12 mg, 68 weeks — highest of any compound ever tested
~75%Knee OA Pain ReductionUnexpected secondary finding in Phase 2 — new indication signal
86%Liver Fat ReductionHepatic steatosis — glucagon receptor adds thermogenic pathway
TripleGIP + GLP-1 + GlucagonFirst triple-agonist — three receptors, one molecule
Weight Loss Progression vs Dual & Single Agonists
Head-to-head trajectory comparison (separate trials)
Retatrutide (68 wk)28.7%
Tirzepatide (72 wk)22.5%
Semaglutide (68 wk)14.9%
Cross-trial comparison

Need-to-Know

  • Room Temperature (Lyophilized): 2-3 weeks
  • Refrigerated (Reconstituted): Up to 30 days (do not freeze reconstituted)
  • Frozen (Lyophilized): 24-36 months
  • Reconstitution Solution: Bacteriostatic water
  • Appearance: White powder

Regulatory Status

Not FDA-approvedInvestigationalPhase 3

Phase 3 trials for obesity. Phase 2 demonstrated up to 24% weight loss. Anticipated regulatory decision 2025-2026.

Sources: ClinicalTrials.gov

History

2010s
Developed as first triple-action weight loss drug; animal studies showed strong effects.
2020s
Phase 2 showed 24.2% weight loss; Phase 3 trials launched for obesity and diabetes.

3D Structure

38-amino-acid peptide · 4731.33 g/mol

Interactive model
Retatrutide molecule previewExplore 3D Structure

Retatrutide at the Cellular Level

Triple receptor agonist

Mechanism
Retatrutide cellular mechanism preview

Retatrutide in the Body

Triple GLP-1/GIP/glucagon agonist

Metabolic
Retatrutide in the Body

Research Library

Peer-reviewed studies

From Published Literature

"Phase 2 trials indicate that Retatrutide, a triple-hormone-receptor agonist, demonstrates dose-dependent efficacy in reducing body weight in adults with obesity."

Ania M. JastreboffNew England Journal of Medicine
Verify on PubMed

Complete Your Protocol

Complementary compounds from other research areas